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Abstract
50-AMP-activated protein kinase (AMPK) is an energy sensor that controls cell metabolism, and it has been
related to apoptosis and cell-cycle arrest. Although its role in metabolic homeostasis is well documented, its
function in cancer is much less clear. In this study, we examined the role of AMPK in a mouse model of
astrocytoma driven by oncogenic H-RasV12 and/or with PTEN deletion based on the common constitutive
activation of the Raf/MEK/ERK and PI3K/AKT cascades in human astrocytomas. We also evaluated the
activity and role of AMPK in human glioblastoma cells and xenografts. AMPK was constitutively activated in
astrocytes expressing oncogenic H-RasV12 in parallel with high cell division rates. Genetic deletion of AMPK
or attenuation of its activity in these cells was sufficient to reduce cell proliferation. The levels of pAMK were
always related to the levels of phosphorylated retinoblastoma (Rb) at Ser804, which may indicate an AMPK-
mediated phosphorylation of Rb. We confirmed this AMPK–Rb relationship in human glioblastoma cell lines
and xenografts. In clinical specimens of human glioblastoma, elevated levels of activated AMPK appeared
especially in areas of high proliferation surrounding the blood vessels. Together, our findings indicate that
the initiation and progression of astrocytic tumors relies upon AMPK-dependent control of the cell cycle,
thereby identifying AMPK as a candidate therapeutic target in this setting. Cancer Res; 73(8); 2628–38. 2013
AACR.
Introduction
In the 1920s, a relationship between cellularmetabolism and
tumorigenesis was first proposed by Warburg and colleagues,
showing that cancer cells exhibited an increase in glycolysis
even in conditions of high oxygen levels (1). Since then many
modifications in intermediary metabolism have been
described in cancer cells, but the molecular mechanisms that
interconnect the signaling pathways controlling metabolism
and cell growth have only begun to be elucidated. One of the
plausible links between cell metabolism and cancer is the fuel-
sensing enzyme 50-AMP-activated protein kinase (AMPK). This
kinase has a major role in the regulation of glucose, lipid, and
protein metabolism in response to stimuli such as changes in
fuel availability, oxidative stress, heat shock, and hormones (2).
AMPK is a heterotrimer that contains 1 catalytic (a1 or a2), 1
regulatory (b1 or b2), and 1 AMP/ATP–binding (g1, g2, or g3)
subunit (2). Decreases in the cellular energy state, as reflected
by an increase in the AMP/ATP ratio, induce conformational
changes in AMPK thatmakes it susceptible to phosphorylation
and activation by AMPK kinases (2). Once activated, AMPK
restores energetic balance stimulating catabolic pathways that
enhance ATP generation and inhibiting others that consume
ATP but are not acutely necessary for survival (3). Recent
findings have also pointed to a link between AMPK and cell
growth. First, it was shown that the tumor suppressor LKB1 is a
kinase that phosphorylates and activates AMPK and that
another tumor suppressor, tuberous sclerosis complex 2
(TSC2), is activated by AMPK (4, 5). TSC2 activation by AMPK
results in suppression of mTORC1 kinase activity. Second,
AMPK was shown to modulate p53-dependent apoptosis by
p53 phosphorylation (6). Third, several studies indicated that
the products of two p53 target genes, sestrin 1 and 2, increased
AMPK activity inducing mTOR signaling inhibition (7). Alto-
gether, these data seemed to indicate a role of AMPK in
cell growth arrest and cell death. Accordingly, activation of
AMPK by energy depletion would function as a metabolic
checkpoint, in which normal cells with intact AMPK signaling
undergo cell-cycle arrest, driving proliferation only when cell
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energy is sufficient to guarantee a successful cell division. It
was shown that some cancer cells exhibit a defective AMPK
activation
(e.g., LKB1 deficiency) or alterations in key components of the
AMPK pathway (e.g., TSC2 or p53 deficiency), which would
uncouple fuel signals from growth signals, allowing tumor cells
to divide under abnormal nutrient conditions. AMPK activa-
tion was then proposed as a therapeutic approach for cancer
(2). However, very recent reports have shown high pAMPK
levels in some tumors and a role of AMPK in tumor cell growth
and survival (8, 9). Therefore, the function of AMPK in the
biology of cancer is far from being understood.
The main objective of the present study was to give further
insight into the regulatory role of AMPK in cell growth and
proliferation in tumors. To accomplish this objective, we
evaluated the function of AMPK in both mice and human
astrocytic tumors. To dissect out the mechanisms underlying
the effect of AMPK in astrocytoma cell growth, we first
reproduced different molecular events that lead from tumor
initiation to progression in the mouse. For this purpose, we
used astrocytes expressing HRasV12 and/or with Pten deletion
because a constitutive activation of Raf/MEK/ERK and PI3K/
AKT cascades are common alterations in human astrocytomas
(10) and both signaling pathways regulate cellmetabolism (11–
13). We then confirmed the role of AMPK in human glioblas-
toma cell lines as well as in human glioblastoma xenografts in
severe combined immunodeficient mice (SCID) mice. Finally,
we examined the level of AMPK activation and activity in
human glioblastoma tissue samples.
Here, we showed that human glioblastomas exhibit high
levels of AMPK activity, and we showed that AMPK activa-
tion is essential for the proliferation of astrocytic tumor
cells by promoting cell-cycle progression in both mice and
human.
Materials and Methods
Cell culture, transfection, and retroviral infection
Cortical astrocytes were obtained from cerebral cortices of
3-day-old Ptenloxp/loxp or AMPKaloxp/Loxp mice and maintained
in culture for 4 to 6 days.AMPKaloxP/loxPmicewere generated as
previously described by crossing AMPKa1loxP/loxP and
AMPKa2loxP/loxP (14, 15). The care and use of experimental
animals was in accordance with institutional guidelines. Cells
were cultured inDulbecco'sModified Eagle'sMedium (DMEM)
supplemented with 10% FBS and to express HRasV12 and/or
Cre-recombinase ecotropic retrovirus were used as previously
published (16).
U87MG andU373MGhuman glioma cell lines were obtained
from J. Seoane (Vall d'Hebron Instituto de Oncología, Barce-
lona, Spain) in 2011. Both cell lines were periodically authen-
ticated by morphologic inspection and tested negative for
Mycoplasma contamination by PCR tests. Cells were cultured
in DMEM supplemented with 10% FBS. For RNA interference
(RNAi) experiments, 3 different commercial AMPKa (a1 and
a2) siRNAs (sc-45312A, sc-45312B, and sc-45312C), and control
siRNA (sc-37007) were obtained from Santa Cruz Biotechnol-
ogy. Transfection of cell lines with 10 and/or 20 nmol/L of
siRNAs was conducted with jetPRIME (Polyplus transfection)
following the manufacturer's recommendations. Cells were
lysed after 48 hours posttransfection and used for subsequent
experiments.
For AMPK activation/inhibition, astrocytes and cell lines
were cultured in the presence of 0.2 mmol/L 5-Aminoimida-
zole-4-carboxyamide ribonucleoside (AICAR) or 10 mmol/L
compound C for the indicated times.
All treatments were conducted in astrocytes cultured for 7
days after the infection in complete medium (DMEM sup-
plemented with 10% FBS) except specifically indicated in the
text.
Tumor growth in SCID mice
SCID mice were fed ad libitum and maintained on a 12-hour
light–dark cycle at a controlled temperature. To estimate the
effect of compoundC in a xenograft tumormodel, tumorswere
induced by subcutaneous injection of 2.5  106 U87MG cells,
resuspended in 100 mL of PBS into the right flank of 6- to 8-
week-old SCID mice (20–25 g). When subcutaneous tumors
had reached a detectable size of 30 mm3, mice were random-
ized into 2 groups: one group was treated with compound C,
administered as a single dose of 10 mg/kg [intraperitoneal
(i.p.)]; the second group received 1 injection of the vehicle (100
mL PBS/DMSO 10%). Mice weremonitored daily for tumor size
(using a calliper) and health status. Tumor volume was cal-
culated by the formula: [(length2  width)/2] until the end of
the experiment (17). When the tumor exceeded 2,000 mm3,
animals were sacrificed and this date was used to plot the
Kaplan–Meier survival curve.
Growth curves and BrdUrd incorporation
We determined cell number in an indirect way using crystal
violet as it has been previously reported (18). To assess relative
cell numbers, cells were grown in 24 multi-well plates and
treated in each case as indicated in the text. At 0, 2, 4, and 7
days, cells were washed with PBS, fixed with methanol:acetic
acid (3:1) for 20 minutes, stained with crystal violet for an
additional 20 minutes, washed 5 times with PBS, and air dried.
Dye was eluted from cells at room temperature by the addition
of 1 mL of 10% acetic acid and absorbances were measured at
595 nm.
DNA replication was determined by detecting bromodeox-
yuridine (BrdUrd) incorporation. Cells grown over 1,7 cm2
coverslips were treated in each case as indicated in the text
and then labeled 5 hours with 10 mmol/L BrdUrd for astrocytes
and 1 hour for cell lines. Cells were fixed with 75% ethanol,
denaturalised for 30 minutes in 4 N HCl, and blocked with 1%
bovine serum albumin. Then, cells were incubated 1 hour at
room temperaturewith anti-BrdUrd antibody andmicroscopic
visualization was possible using a Cy3-tagged secondary anti-
body (Jackson ImmunoResearch). Mounting medium contain-
ing 40,6-diamidino-2-phenylindole (DAPI) was used and cells
were visualized by inmunofluorescence.
Patients and tissue sampling
Human glioblastoma and normal human brain tissue sam-
ples were obtained from patients of the Neurosurgery Service
of the University Hospital of Santiago de Compostela (Santiago
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de Compostela, Spain). The study was conducted after approv-
al of the Ethics committee of the Xunta deGalicia. A small piece
of the tumor and of human brain samples from epilepsy
surgery sent to the Pathological Service was immediately
frozen and used for Western blot analysis. The immunohis-
tochemistry (IHC) was carried out in formalin-fixed paraffin-
embedded samples from human glioblastomas and human
normal brain from the files of the Pathological Service and
Biobank of the University Hospital of Santiago de Compostela.
Data presentation and statistical analysis
Data represent mean  SEM. Before all statistical anal-
yses, data were examined for assumptions of normality of
variance using the Kolmogorov–Smirnov test. The t test,
one-way, or two-way ANOVA were used to calculate statis-
tical significance. Survival curves were estimated by the
Kaplan–Meier method.
Results
AMPK is activated by oncogenic events
We used a cellular model of mice astrocytoma with astro-
cytes expressing HRasV12 and/or with an activated PI3K/AKT
pathway by Pten loss. These signaling pathways are frequently
activated in human astrocytomas (13). Although Ras muta-
tions are not found in human astrocytic tumors, a hyperactiva-
tion of fibroblast growth factor and EGF receptors is frequently
observed, consequently increasing Ras signaling.
As expected, astrocyteswithHRasV12 enhanced extracellular
signal–regulated kinase (ERK)1/2 phosphorylation, and Pten
deletion induced AKT phosphorylation (Supplementary Fig.
S1A and S1B). Ras pathway activation was related with a high
proliferation level, however, no significant changes in cell
growth rate were observed in Pten-null cells (Fig. 1A). Fur-
thermore, we were unable to detect significant levels of apo-
ptosis and senescence in any of the experimental groups, as it
has already been shown (16).
Interestingly an increased AMPK activation, determined by
AMPK phosphorylation at the residue Thr172 (required for the
mammalian AMPK activation), and a higher AMPK activity,
assessed by ACC phosphorylation at the residue Ser79 (a well-
established AMPK target) was found in astrocytes expressing
HRasV12 and/or Pten deletion. A greater effectwas shown in the
cells with oncogenic Ras (Fig. 1B). Total levels of AMPK and
ACC were unchanged (Supplementary Fig. S1C and S1D). This
AMPKactivationwas likely dependent on the oncogenic events
and not due to nutrient depletion caused by a high prolifer-
ation rate because phosphorylation levels of both AMPK and
ACC were increased similarly in cells kept in culture medium
for 7 days, or 24 hours after fresh complete mediumwas added
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Figure 1. AMPK is activated
by HRasv12 expression and Pten
deletion in astrocytes. Neonatal
mice astrocytes were infected
with retroviral vectors encoding
HRasV12 and/or Cre-recombinase,
generating 4 different genotypes:
PtenloxP/loxP, PtenloxP/loxPHRasV12,
Pten/, and Pten/HRasV12.
Cells were maintained in culture for
7 days. Data were represented as
mean  SEM from at least 3
independent experiments. A,
relative cell number determined the
seventh day in culture by crystal
violet (, P < 0.001 vs. PtenloxP/loxP).
B, AMPK activation was examined
by immunoblot analysis of
pAMPKThr172, and pACCSer79.
a-Tubulin was used as a loading
control. C, pAMPKThr172,
pACCSer79, and a-tubulin levels
when cells were cultured
during 7 days (CM7d) or when new
medium was added on the sixth
day in culture 24 hours before
protein extraction (CM 24h). D,
pACCSer79 levels by Western blot
analysis in astrocytes cultured in
the presence of 5.5 or 25 mmol/L
D-glucose.
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the level of activation of AMPK in astrocytes with oncogenic
Ras or Pten loss cultured with either 5 or 25 mmol/L glucose
(Fig. 1D).
AMPK is a mediator of cell proliferation
Previous reports have shown that AMPK activation reduces
cell proliferation by stimulation of TSC2, consequently
inhibiting mTORC1 pathway and by phosphorylation of p53.
However, we show here that astrocytes with oncogenic Ras,
with or without AKT activation maintained high prolifera-
tion rates in the presence of an elevated AMPK activity.
HRasV12-expressing astrocytes and cells without Pten exhib-
ited levels of pmTORSer2448 similar to those observed in
control cells (Supplementary Fig. S2A). These results prob-
ably reflect that AMPK was counteracting the effect of Ras
and AKT on TSC2, inhibiting the anabolic effects of both
signaling pathways.
To determine possible roles of oncogenic AMPK activa-
tion, we first analyzed pAMPK cell localization. Immuno-
fluorescence analysis showed that pAMPK was mainly local-
ized in the cytoplasm of control cells, whereas oncogenic
events induced an increase in pAMPK nuclear levels (Fig. 2A
and B). As it has previously been shown that AMPK nuclear
localization was related to a higher expression of AMPKb1
(19), we determined the levels of both AMPKb1 and
AMPKb2. Interestingly, we found increased AMPKb1 levels
in HRasV12 and Pten/ cells and a reduced content of
AMPKb2 in HRasV12 astrocytes (Fig. 2C and Supplementary
Fig. S2C). Furthermore, subcellular fractionation data con-
firmed a nuclear increase in pAMPK and pRbSer800/804 levels,
a recently described AMPK target (19), in these groups of
cells (Fig. 2D). Nuclear to cytoplasmic ratio (Nuc:cyt) of
pAMPK was significantly increased in oncogenic Ras-expres-
sing cells (Supplementary Fig. S2D). On the other hand, total
AMPKa levels were also increased in the nuclear fraction in
the astrocytes with the oncogenic events (Supplementary
Fig. S2B).
Wenext investigatedwhether AMPKactivation or inhibition
had any effect on the proliferative capacity of our cells. To
accomplish this, we used AICAR (an adenosine analog, rapidly
phosphorylated, whichmimics the activating effects of AMPon
AMPK) or compound C (a compound that acts as a potent,
selective, reversible, and ATP-competitive inhibitor of AMPK).
Accordingly, astrocytes after 6 days in culture were incubated
with AICAR or with compound C for 24 hours and BrdUrd
incorporation was evaluated. In agreement with previous
reports, AICAR induced AMPK activation, determined as
higher levels of pACC, but concentrations higher than 0.2
mmol/L reduced normal astrocytes viability (Supplementary
Fig. S2E and S2F). We treated then the cells with AICAR at a
concentration of 0.2 mmol/L. Expression of oncogenic Ras
induced a significant increase in BrdUrd incorporation, but
treatment with 0.2 mmol/L AICAR for 24 hours did not change
the levels of BrdUrd incorporation exhibited by nontreated
cells (Fig. 2E). Interestingly, cells treated with compound C at
concentrations that allowed cell viability in control astrocytes
and previously described to reduce AMPK activation
(refs. 9, 20–22; 10 mmol/L; Supplementary Fig. S2G) signifi-
cantly reduced BrdUrd incorporation in the cells expressing
HRasV12 (Fig. 2F). Decreased levels of pRb800/804 accompanied
this reduction, whereas no effect on the phosphorylation of
retinoblastoma (Rb) was shown after treatment with AICAR
(Fig. 2G and Supplementary Fig. S2H). These results suggest a
mechanism by which AMPK regulates proliferation in astro-
cytoma cells with a hyperactivated Ras pathway.
AMPK is necessary to maintain cell proliferation inmice
astrocytes expressing oncogenic Ras and in human
glioblastoma cell lines
To further show the relationship between AMPK, Rb, and
proliferation, we used primary cultures of AMPKa-deficient
mice astrocytes. We studied the effect of AMPK deletion
only in normal and in astrocytes expressing HRasV12 because
Pten loss showed a very moderate effect on the parameters
evaluated.
Astrocytes from mice with both AMPK catalytic subunits
floxed were infected with H-RasV12 and/or Cre-recombinase.
As expected, AMPKa deletion reduced AMPKa levels and
AMPK activity, as shown by ACC phosphorylation; the infected
astrocytes withHRasV12 enhancedHRas levels (Supplementary
Fig. S3A).
Cell growth rate and foci formation in astrocytes expressing
HRasV12were reduced byAMPKdeletion, whereas no effectwas
shown in control cells. (Fig. 3A and B). Furthermore, growth
inhibition in cells with oncogenic Ras expression and AMPK
deletion was not further increased when compound C (10
mmol/L) was added to the culture medium for 7 days (Sup-
plementary Fig. S3B).
Proliferation, senescence, and apoptosis were determined in
these cells. BrdUrd incorporation was determined in cells after
7 days in culture. Astrocytes with HRasV12 and AMPK deletion
showed a remarkable reduction in proliferation, with levels of
BrdUrd incorporation within the range of control cells. Curi-
ously, AMPK-null cells continued to proliferate as control
astrocytes (Fig. 3C). On the other hand, only a very low
senescence increase was observed in cells with AMPK deletion
and HRasV12 expression (Supplementary Fig. S3C), whereas no
change in the levels of apoptosis was detected among the
different groups (data not shown).
Finally, we determined pRbSer800/804 levels in the 4 experi-
mental groups. In agreement with our results with compound
C, we found a reduction in pRbSer800/804 in AMPK-deficient
cells, in parallel to a decrease in ACC phosphorylation (Fig. 3D).
Thismight explain the reduced rate of proliferation observed in
AMPK-deleted astrocytes and confirm the important role of
AMPK in maintaining the proliferation induced by HRasV12.
Because of the importance of AMPK in the proliferation of
mice astrocytes expressing HRasV12 and/or Pten deletion, a
plausible role of this kinase in human glioblastoma cells
growth and proliferation was also investigated. We used
U87MG and U373MG cell lines, as previous reports had shown
that these astrocytoma/glioblastoma cell lines did not have
mutations in the Rb gene (23, 24) We first inhibited AMPK
activity with compound C (10 mmol/L; 7 days). Interestingly,
this treatment blocked cell growth even in the U87MG cell line,
which exhibits a more aggressive phenotype than the U373MG
AMPK Is Necessary to Maintain Glioblastoma Proliferation
www.aacrjournals.org Cancer Res; 73(8) April 15, 2013 2631
on February 3, 2021. © 2013 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 













































































– + – + – + – +


















































Figure 2. HRASV12 expression induces nuclear pAMPK localization and subsequently Rb phosphorylation. Astrocytes of the 4 different genotypes
PtenloxP/loxP, PtenloxP/loxPHRasV12, Pten/, and Pten/HRasV12 were maintained in culture for 7 days. Data are represented as mean SEM from at least 3
independent experiments. A, representative confocal microphotographs of pAMPKThr172 immunofluorescence showing its nuclear and cytoplasmatic
localization. Scale bar, 100 mm. B, nuclear and cytoplasmic fluorescence was quantified for each cell and the percentage of cells with a ratio of
nucleus/cytoplasmpAMPKThr172 fluorescence>2.5was represented (,P<0.05 vs.PtenloxP/loxP). C, AMPKb1, AMPKb2, anda-tubulin levelswere determined
by immunoblotting. D, cytoplasmic and nuclear extracts were used to determine pAMPKThr172 and pRbSer800/804. Levels of a-tubulin and b-lamina
were used as control. E and F, cells were treated with 0.2 mmol/L AICAR or 10 mmol/L compound C for 24 hours on the seventh day in culture. E, percentage
of BrdUrd-positive astrocytes (, P < 0.001 vs. PtenloxP/loxP). F, pACCSer79, pRbSer800/804, and a-tubulin levels determined by immunoblotting.
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Figure 3. AMPK deletion, inhibition, or knocked down reduces growth in astrocytes-expressing HRASV12 and human glioblastoma cell lines. Astrocytes of
4 different genotypes AMPKloxP/loxP, AMPKloxP/loxPHRasV12, AMPK/, and AMPK/HRasV12were maintained in culture for 7 days. Data are represented as
mean  SEM from at least 3 independent experiments. A, representative microphotographs of cells stained with crystal violet. Scale bar, 100 mm.
B, growth curve showing relative cell number of the 4 experimental groups. C, percentage of BrdUrd-positive astrocytes (, P < 0.001 vs. AMPKloxP/loxP).
D, levels of pAMPKThr172, pACCSer79, pRbSer800/804, and a-tubulin levels byWestern blot analysis. E, F and G, U87MG andU373MG cells were treated with or
without 10 mmol/L compound C for 7 days. E, representative microphotographs of crystal violet staining. F and G, growth curve showing relative cell number.
H and I, U87MGandU373MGcells were treatedwith 10 mmol/L compoundC for 24 hours. H, percentage of BrdUrd-positive cells. I, pACCSer79, pRbSer800/804,
anda-tubulin levels by immunoblotting. J and K, U87MG andU373MG cells were transfected with 10 to 20 nmol/L of scrambled or AMPKa siRNA (48 hours).
J, percentage of BrdUrd-positive cells. K, pAMPKThr172, pACCSer79, pRbSer807/811, and a-tubulin were determined by Western blot analysis (, P < 0.05
vs. control conditions).
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(Fig. 3E–G). Consistent with our previous results in mice
astrocytes, compound C significantly reduced BrdUrd incor-
poration in both glioblastoma cell lines (Fig. 3H) with no effect
on senescence or apoptosis (data not shown). Moreover, we
found lower levels of Rb phosphorylation in Ser807/811 (corre-
sponding to Ser800/804 inmouse), in parallel to a pACC-reduced
content in the cells treated with compound C (Fig. 3I). This
effect of compound C suggested a similar role of AMPK on cell-
cycle regulation in mice astrocytes expressing HRasV12 and/or
Pten loss and in human glioblastoma cell lines.
To firmly establish a direct relationship between AMPK
inhibition, Rb phosphorylation, and cell growth in these cells
lines, we knocked down AMPK with siRNAs targeting the
catalytic subunits of AMPK (a1 and a2). We studied the
efficacy of 3 different siRNAs in reducing AMPKa levels and
activity, by transfecting U87MG glioblastoma cells with the
siRNAs (20 nmol/L; 48 hours), separately or in combinations.
All siRNAs tested reduced AMPK levels and activity, as deter-
mined by pACC levels, although with different degrees of
efficiency. The combination of the 3 pooled siRNAs reduced
AMPKa and pACC levels further (Supplementary Fig. S3D and
S3E). Likewise, individual and pooled siRNAs reduced
pRb807/811 levels and BrdUrd incorporation. The decrease was
greater with the 3 siRNAs together (Supplementary Fig. S3D–
S3F). Finally, we transfected U87MG and U373MG cells with
the 3 pooled AMPK siRNAs (10 and 20 nmol/L; 48 hours), and
we showed a significant reduction in BrdUrd incorporation
and pRb807/811 levels in both cell lines (Fig. 3J and K).
All these data showed the relevance of AMPK in human
glioblastoma cell proliferation.
AMPK inhibition decreases the in vivo growth of
xenografts of human glioblastoma cell lines
Wehave shown that AMPK inhibition reduced cell growth in
human andmurine astrocytic tumor models in vitro. However,
stress conditions characteristic of a solid tumor microenvi-
ronment (hypoxia andmetabolic stress)might affect the role of
AMPK. To determine the effect of compound C on the growth
of human glioblastoma cells in vivo, we injected U87MG tumor
cells, subcutaneously, in immunodeficient SCID mice. We
chose these cells because they are very tumorigenic in vivo in
contrast to U373MG cells, which has been shown not to
develop tumors in animals (25). Consistent with our in vitro
findings, one single dose of compound C (10 mg/kg, i.p.) was
able to reduce significantly the growth rate of U87MG tumors
(Fig. 4A) and this treatment increased the survival of tumor-
bearingmice (Fig. 4B). We were unable to detect a higher effect
when we treated the mice with several doses of compound C
(Supplementary Fig. S4), which suggests that AMPK inhibition
with compound Cmight produce a selection against growth of
tumor cells with this pathway activation. In any case, our data
reflect the important role of AMPK during in vivo glioblastoma
tumor progression.
To further analyze the molecular mechanisms underlying
this effect of AMPK, we determined apoptosis as well as cell
proliferation levels in the tumor samples. IHC of cleaved
caspase-3 did not show significant changes between tumors
in animals with or without treatment (Fig. 4C). However,
tumors in mice treated with compound C showed a reduction
in BrdUrd incorporation and in the levels of p-histone H3 (Fig.
4C and D), showing once again the relevant effect of AMPK in
the control of cell proliferation. Finally, we studied the plau-
sible AMPK-pRb signaling pathway in the tumors of animals
with and without compound C treatment. Interestingly, Rb
phosphorylation was decreased in parallel with a reduced
AMPK activity (estimated by pACC Ser79 levels) in U87MG
tumors treated with the AMPK antagonist (Fig. 4E). These
results further illustrate that AMPK inhibiton reduce in vivo
tumorigenesis.
AMPK is activated in human glioblastomas
To determine whether AMPK is activated in human glio-
blastomas, we carried out IHC to detect pACCSer79 on tissue
samples from glioblastomas of 10 patients (Table 1 and Fig.
5A). Negative controls consisting of omission of primary
antibody or substitution of primary antibody by normal rabbit
serum (NRS) were conducted (Supplementary Fig. S5). High
levels of pACCSer79 were observed in 100% of the tumors
evaluated (Table 1). Normal brain tissue was either completely
negative or showed only a weak staining for pACCSer79 (see
representative photographs in Fig. 5A). In contrast, all glio-
blastoma tissue samples showed a heterogeneous pattern of
positive cells. The immunoreactivity was found predominant-
ly, if not entirely, in the cytoplasm. The highest number of
pACCSer79 immunoreactive cells was found in areas surround-
ing the blood vessels. We also determined Ki67 immunoreac-
tivity as a proliferation index, and we found a good correlation
between Ki67 and pACCSer79 immunoreactive levels, especially
around the blood vessels (Table 1 and Fig. 5A). Very interest-
ingly, high levels of pERKThr202/Tyr204 were found in all the
tumors evaluated in this study, especially in perivascular
regions and areas with high proliferative rate (Table 1
and Fig. 5A). This localization of pACC cells shows that, in
human glioblastomas, oncogenic events but not hypoxia,
energy depletion, or low nutrients availability are responsible
for AMPK activation. Finally, to further establish a relationship
between AMPK activation and proliferation in human glio-
blastomas, we determined pAMPK, pACC, and pRb807/811 by
Western blot analysis in 4 tissue samples of human glioblas-
tomas and human normal brain. We found higher levels of
pAMPKThr172 and pACCSer79 in the 4 tumors in relation with
normal tissues, in agreement with the results of IHC (Fig. 5B).
Furthermore and consistent with our previous results in mice
astrocytes and in human glioblastoma cell lines, AMPK acti-
vation in the human glioblastoma tissue samples studied here
was accompanied by high levels of pRb807/811.
In conclusion, our results show that AMPK has an impor-
tant role in tumor growth, suggesting that an AMPK antag-
onist might potentially be used as a treatment in astrocytic
tumors.
Discussion
While in various cancer cells a loss of appropriate AMPK
signaling has been shown and AMPK activation has been
proposed as a therapeutic approach to reduce cancer cell
growth (2) in some others an activation of AMPK has been
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found, and a role of AMPK as a prosurvival factor in tumor cells
has been described (9, 26).
In the present study, we evaluated the function and mech-
anism of action of AMPK in cell growth and proliferation in
murine and human astrocytic tumors.
The novel and striking result of this study was the finding of
AMPK as inductor of proliferation in these tumor cells. Spe-
cifically, we show here that oncogenic Ras and Pten deletion
activates AMPK and that this activation stimulates cell pro-
liferation. Furthermore, human glioblastoma exhibits elevated
levels of activated AMPK and inhibition of AMPK in astrocytes
expressing HRasV12 or in human glioblastoma cells significant-
ly reduces cell growth.
A recent report has shown high pAMPK levels in rat gliomas
(8), and it was shown that AMPK inhibition in prostate cancer
cells or in mouse embryonic fibroblasts transformed by onco-
genic Ras and SV40 large T-antigen reduced tumor growth
(9, 27). Nevertheless, in these reports it was hypothesized that
AMPK activation was a consequence of hypoxic or ischemic
microenvironments. Here, we found that AMPK was highly
activated in astrocytes expressing oncogenic Ras and Pten
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Figure 4. AMPK inhibition reduces tumor growth ratio in a xenograft model. U87MG cells were injected subcutaneously in SCID mice and when the tumors
achieved 30 mm3 in size, mice were treated intraperitoneally with 10 mg/kg compound C or vehicle. A, tumor volume in mice treated with vehicle
(n¼ 6) or compoundC (n¼ 7). B, Kaplan–Meier curves ofmice treatedwith vehicle (n¼ 6) or compoundC (n¼ 7; ,P < 0.0012 vs. animals treatedwith vehicle).
C, representative microphotographs of inmunohistochemistry showing BrdUrd incorporation, pHistone H3Ser10, and cleaved caspase-3 in tumors
8 days after vehicle or compoundC treatment. Scale bar, 100 mm. D, percentage of BrdUrd-positive cells in U87MG tumors 8 days after vehicle or compound
C treatment (, P < 0.0001 vs. nontreated tumors). E, ACCSer79, pRbSer807/811, and a-tubulin levels were determined by Western blot analysis in U87MG
tumors 8 days after vehicle or compound C treatment.
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after fresh culture medium was added to the cells, or in the
presence of high concentrations of glucose (25 mmol/L),
indicating that oncogenic signaling pathways, but not hypoxia
or glucose depletion, were responsible for this activation.
Moreover, the localization of cells with high levels of AMPK
activity (determined as levels of pACC) in human glioblasto-
mas, surrounding blood vessels, in areas with a high Ki67
proliferative index and high levels of pERK gives further
support to this idea. In fact, it has been reported that AMPK
activity may also be elevated under nonstressed conditions, for
example by hormones such as leptin, adiponectin, and inter-
leukin-6 (28). Curiously enough these adipokines have been
implicated in the development and progression of some
human cancers (29).
The activation of AMPK observed in astrocytes with onco-
genic events and in the human glioblastomas probably indi-
cates that AMPK provides metabolic support by directing cells
to generate ATP to maintain energy homeostasis in these
demanding conditions of high rate division. However, as our
results suggest, the role of AMPK in cancer cells is not
restricted to regulation of ATP levels, but is also involved in
cell proliferation.
AMPK can be found both in the nucleus and the cytoplasm
(30), and in mammalian cells, leptin (31) heat shock, and
different types of stress (32, 33) have been reported to regulate
the AMPK nuclear translocation. In this work, we show that
nuclear localization of pAMPK was increased by HRasV12
expression or Pten loss. Previous data have related AMPKb1
to nuclear localization of AMPK (19). In our hands, astrocytes
with the oncogenic events exhibited higher levels of the
AMPKb1 subunits and a reduced content of the AMPKb2,
which reinforces the hypothesis of an important function of
AMPK at the nuclear level in these cells. The increase of the
nuclear localization of pAMPK would enhance the phosphor-
ylation of its nuclear targets. Interestingly, it was recently
shown that AMPK is an important kinase of Rb, specifically at
Table 1. Human glioblastomas show high levels of AMPK activity and pRbSer807/811 levels
N Method Na pACC pACC perivascular pRb pERK
Glioblastoma 14 IHC 10 þ þ n/a þ
WB 4 þ n/a þ n/a
Normal tissue 8 IHC 4   n/a 
WB 4  n/a  n/a
NOTE: Human glioblastoma tissue samples and human normal brain tissue analyzed by IHC orWestern blot (WB) analysis. High levels
(þ) and low levels () of immunoreactivity.
Abbreviation: n/a, not available.

























Figure 5. AMPKactivity is increased
in human glioblastomas especially
in areas of high proliferation. A,
representative microphotographs
of normal human brain and human
glioblastoma tissue samples
stained with hematoxylin
and eosin or processed by
IHC to detect pACCSer79, Ki67,
and pERKThr202/Tyr204. Scale bar,
100 mm. B, lysates of normal
brain and glioblastoma tissue
samples were used to determine
pAMPKThr172, pACCSer79,
pRb Ser807/811, and a-tubulin
levels by immunoblotting
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Ser800/804, and that this phosphorylation has a key role during
brain development by cell-cycle regulation (19). Our data
showed that the increase of nuclear pAMPK by HRasV12
expression and/or Pten deletion was accompanied by higher
levels of pRbSer800/804, and this correlationwas also found in the
human glioblastoma cells lines. Furthermore, AMPK inhibition
in mice astrocytes with compound C or AMPK deletion
reduced significantly HRasV12-induced cell growth by decreas-
ing BrdUrd incorporation and pRbSer800/804 levels. This funda-
mental role of AMPK in regulating cell growth was also shown
in U87MG and U373MG cell lines by blocking the expression of
AMPK with siRNA or inhibiting AMPK activity by using com-
pound C.
Finally, we could demonstrate that a single intraperitoneal
dose of compound C significantly decreased tumor growth of
U87MG xenografts, increasing the survival of the tumor-bear-
ing mice. Once more when we studied the molecular mechan-
isms underlying this inhibitory effect, we found reduced levels
of pRbSer807/811 and proliferation.
The evidence presented here that AMPK activation and
activity is induced early and remains elevated in human
glioblastoma contributes to our understanding of the role of
AMPK in astroglial tumor development, a type of brain tumors
with a very poor survival rate. A better knowledge of tumor
biology is essential for more specific targeting and the devel-
opment of pharmacologic methods of treatment.
In conclusion, although it has been shown that AMPKacts as
a survival factor protecting cells from hypoxia and nutrient
deprivation, limiting ATP use in these situations (27, 34–37),
AMPK is not required for growth in normal cells with abun-
dance of nutrients. In contrast, in oncogenic situations (e.g., in
the presence of oncogenic Ras signaling), AMPK activation is
essential for cell growth and proliferation by regulating Rb
phosphorylation, and therefore cell-cycle progression. By put-
ting all these data together, we propose that the use of AMPK
inhibitorsmight be a good therapeutic approach in tumor cells
with high levels of pAMPK.
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